脓毒症新发房颤的危险因素分析
摘要
关键词
全文:
PDF参考
Cohen J. The immunopathogenesis of sepsis [J]. Nature, 2002, 420(6917): 885-891.
Angus D C, Van Der Poll T. Severe sepsis and septic shock[J]. N Engl J Med, 2013, 369(9): 840-851.
Aviles R J, Martin D O, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation[J]. Circulation, 2003, 108(24): 3006-3010.
Gundlund A, Olesen J B, Butt J H, et al. One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study[J]. Eur Heart J, 2020, 41(10).
Walkey A J, Wiener R S, Ghobrial J M, et al. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis[J]. Jama, 2011, 306(20): pages.
Moss T J, Calland J F, Enfield K B, et al. New-Onset Atrial Fibrillation in the Critically Ill[J]. Crit Care Med, 2017, 45(5).
Bosch N A, Cimini J, Walkey A J. Atrial Fibrillation in the ICU[J]. Chest, 2018, 154(6): 1424-1434.
Singer M, Deutschman C S, Seymour C W, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)[J]. Jama, 2016, 315(8): 801-810.
Annane D, Ouanes-Besbes L, De Backer D, et al. A global perspective on vasoactive agents in shock[J]. Intensive Care Med, 2018, 44(6): 833-846.
Eengelmann M D, Svendsen J H. Inflammation in the genesis and perpetuation of atrial fibrillation[J]. Eur Heart J, 2005, 26(20): 83-92.
DOI: https://doi.org/10.12346/pmr.v4i6.7961
Refbacks
- 当前没有refback。